Ovagen: A Research Overview of the EDL Liver Bioregulator

Ovagen is one of the Khavinson “bioregulator” peptides — ultra-short sequences from a long-running Russian research program —, and it carries the family’s usual caution: a real but narrow, largely single-program literature, and a headline mechanism that is more hypothesis than established fact. Within that, Ovagen has a handful of genuinely indexed citations. An honest overview credits what is documented while being clear about the limits.

This summary describes what the chemical record and the published literature report about Ovagen — its identity, its proposed mechanism, the nature of its evidence, and its regulatory status. It describes findings as they appeared in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Ovagen Is

Ovagen is a synthetic tripeptide with the sequence glutamic acid-aspartic acid-leucine (Glu-Asp-Leu, EDL), formula C₁₅H₂₅N₃O₈, roughly 375 g/mol. It was developed within the program led by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, derived by analysis of liver-tissue peptide preparations and positioned as a liver and gastrointestinal bioregulator (Ovagen identity (EDL tripeptide), research-use note).

A product-identity caution worth flagging: in commercial channels, “Ovagen” is sometimes sold as an “AC-3” peptide complex or described only by its constituent amino acids, which is not the same as confirming the defined EDL tripeptide is present in the correct sequence and purity (AC-3 / complex-product caution). Treat “Ovagen” as a brand/research name unless a certificate of analysis confirms the EDL tripeptide for the specific material in question.

Proposed Mechanism

Ovagen is proposed to act through the mechanism shared across the Khavinson family: rather than binding cell-surface receptors, the peptide is hypothesized to enter the cell, reach the nucleus, and interact with DNA or chromatin to influence gene transcription — here, in liver and gastrointestinal cells, with a framing around supporting protein synthesis, antioxidant defense, and hepatocellular function. As with the rest of the family, the direct-DNA-regulation model is the program’s defining hypothesis and is not widely established in the broader molecular biology literature. “Proposed” is the operative word.

The Evidence Base

Ovagen’s evidence is preclinical and originates overwhelmingly from the Khavinson program and collaborators, with several indexed citations — for example, work in Biochemistry (Moscow) and Bulletin of Experimental Biology and Medicine, and biogerontology studies on peptide bioregulators (indexed citation list, research-use page). The work is at the cell and animal levels and is framed around hepatic regulation and aging.

There is no published controlled human clinical trial of Ovagen demonstrating efficacy or long-term safety. Claims of “detoxification,” “liver repair,” or digestive benefit describe a hypothesis plus animal/cell observations, not demonstrated human outcomes. The honest characterization is a preclinically studied research peptide with some indexed animal data and no human trial validation.

• Findings come from cell and animal studies, overwhelmingly from one research program and its collaborators.
• No controlled human clinical trials of Ovagen exist; human-level claims are not established.
• Commercial “Ovagen” products vary in whether they contain the defined EDL tripeptide.

Regulatory Status

The status below reflects mid-2026 and may change; verify against current sources before relying on it. Ovagen is not FDA-approved for any indication in the United States. It is sold as a research-grade compound for laboratory use only and, by its labeling, is not intended for human consumption. In some markets, these bioregulators are sold within supplement-style categories, which are regional regulatory classifications rather than evidence of efficacy. Like other Khavinson peptides, it sits outside the FDA’s 503A peptide-compounding framework and has no established clinical or compounded access pathway in U.S. practice.

Why Ovagen Appears in Research Discussions

The conceptual appeal is the family-wide one — the idea that an ultra-short, tissue-associated peptide might act as a gene-level regulator of its source tissue, here the liver and digestive tract. The accurate framing remains carefully qualified: a defined tripeptide, a preclinical record concentrated in one program (though partly indexed), an unproven direct-DNA mechanism, product-identity ambiguity in the marketplace, and no human clinical validation. It is a reasonable object of laboratory curiosity, not an established hepatic therapy.

For deeper reading, the indexed primary studies cited here are the best starting point. Ovagen is best understood alongside the other Khavinson bioregulators — see the related Pinealon, Vilon, Cortagen, Cardiogen, Cartalax, and Chonluten overviews — and the wider class is collected in our peptide research library.

A note on the evidence base: Independent, peer-reviewed evidence in English is limited; the available literature on Ovagen is overwhelmingly from the research group (the Khavinson program) and its collaborators and has not been widely replicated by independent laboratories. The citations below reflect that literature, and readers should weigh it accordingly.